See also this year's filing and all EDGAR filings for this company.
PDF Report 0001831363_2022_Terns_Pharmaceuticals_Inc.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'100040 - Statement - Statements of Operations and Comprehensive Loss 2': 5, '100050 - Statement - Statements of Operations and Comprehensive Loss': 14}} |
Graph
Absolute values for 0001831363, Terns Pharmaceuticals Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 166,930,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 1,046,000 |
| 3 | remainder_Assets | 94,000 |
| 4 | LiabilitiesCurrent | 6,820,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 947,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 19,549,000 |
| 9 | ResearchAndDevelopmentExpense | 31,311,000 |
| 10 | remainder_Expenses | 508,000 |
| 11 | remainder_Revenues | 1,000,000 |
| 12 | remainder_NetIncome | 210,000 |
| 13 | remainder_ComprehensiveNetIncome | -214,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 168,070,000 |
| 1 | Liabilities | 7,767,000 |
| 2 | Expenses | 51,368,000 |
| 3 | Revenues | 1,000,000 |
| 4 | StockholdersEquity | 160,303,000 |
| 5 | NetIncome | -50,158,000 |
| 6 | ComprehensiveNetIncome | -50,265,000 |
| 7 | BaseVar | 114,314,500 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 3.40 |
| 9 | EconomicCapitalRatio | 3.96 |
Edgar->Model Mapping
Feature Distribution
